《抗击新冠肺炎疫情的中国行动》白皮书（双语全文）(80)

坚持科研攻关和临床救治、防控实践相结合。第一时间研发出核酸检测试剂盒，推出一批灵敏度高、操作便捷的检测设备和试剂，检测试剂研发布局涵盖核酸检测、基因测序、免疫法检测等多个技术路径。坚持“老药新用”基本思路，积极筛选有效治疗药物，探索新的治疗手段，在严谨的体外研究和机制研究基础上，不断总结救治经验，推动磷酸氯喹、恢复期血浆、托珠单抗和中医药方剂、中成药等10种药物或治疗手段进入诊疗方案，获得4项临床批件，形成5项指导意见或专家共识。开展试验性临床治疗，加快推广应用临床验证有效的诊疗方法和药物。强化实验室生物安全监管，加强新冠病毒临床检测血液样本和实验室检测生物样本管理。Scientific R&D has been integrated with clinical treatment and epidemic control.Having promptly developed nucleic acid test kits, China has also introduced a range of high-sensitivity, easy-to-use test equipment and reagents. Its R&D of reagents covers nucleic acid testing, gene testing, and immunological testing.Putting existing medicines to new use, China has searched for effective medicines and new therapies, and summarized clinical experience based on rigorous in vitro experiments and pathogenic research. Ten types of medicine, including chloroquine phosphate, tocilizumab, finished TCM drugs, and herbal preparations, as well as convalescent plasma therapy, have been adopted in treatment plans. Approval for clinical trial has been given to four medicines, and guidelines formed or expert consensus reached in five areas. Clinical treatments have been trialed, and diagnosis and treatment methods and medicines that have proven clinically effective have been rolled out at a faster pace. Biosecurity has been strengthened at laboratories, as has the management of blood samples for Covid-19 testing and biological samples for laboratory testing.